Table 3.
Univariate analysis of PFS and OS
| 65–69 years | 70–91 years | ||||||||||
| n | PFS | OS | n | PFS | OS | ||||||
| mPFS | P | mOS | P | mPFS | P | mOS | P | ||||
| Sex | Male | 10 | 9.9 | 0.91 | 10 | 0.46 | 41 | 6.9 | 0.58 | 9.5 | 0.20 |
| Female | 11 | 10.1 | 28.6 | 29 | 7.6 | 16.1 | |||||
| CCI | Low (0 point) | 18 | 9.9 | 0.88 | 22.8 | 0.66 | 39 | 10.2 | 0.40 | 12.8 | 0.52 |
| Medium-high
(≥1point) |
3 | 30.2 | 28 | 31 | 4.2 | 9.9 | |||||
| WHO Grade | III | 1 | 7.9 | 0.49 | 39.2 | 0.7 | 18 | 8.5 | 0.81 | 11.4 | 0.84 |
| IV | 20 | 10.1 | 21.3 | 52 | 6.3 | 12.7 | |||||
| EOR | Gross total removal | 7 | 14 | 0.005 | 22.1 | 0.17 | 9 | 11.3 | 0.83 | 11.3 | 0.82 |
| Partial removal | 10 | 14 | 33.1 | 25 | 11.5 | 14.9 | |||||
| Biopsy | 4 | 4.3 | 9.9 | 36 | 6.3 | 10.1 | |||||
| MGMT | Immunopositive
(≥10%) |
12 | 9.9 | 0.65 | 22.8 | 0.69 | 35 | 6.6 | 0.91 | 12.9 | 0.65 |
| Immunonegative
(<10%) |
6 | 10.1 | 18.5 | 24 | 6.9 | 11.6 | |||||
| No test | 3 | 7.3 | 29.3 | 11 | 8.5 | 9.5 | |||||
| Preop. KPS | ≥70 | 12 | 9.2 | 0.38 | 29.3 | 0.82 | 29 | 12.3 | 0.01 | 16.8 | 0.01 |
| ≤60 | 9 | 10.1 | 18.5 | 41 | 5.5 | 9.1 | |||||
| Postop. KPS | ≥70 | 11 | 20.7 | 0.003 | 29.2 | 0.33 | 22 | 12.3 | 0.002 | 18.4 | 0.002 |
| ≤60 | 10 | 7.9 | 10.1 | 48 | 5.5 | 9.1 | |||||
| Adjuvant therapy | Chemoradiation | 19 | 11.5 | 0.48 | 16.1 | 0.44 | 41 | 11.4 | 0.06 | 16.1 | 0.02 |
| Others | 2 | 7.2 | 11.4 | 29 | 6.2 | 9.1 | |||||
| Salvage therapy | Yes | 8 | 20.7 | 0.3 | 28.9 | 0.5 | 21 | 8.5 | 0.39 | 17.3 | 0.04 |
| No | 13 | 7.9 | 12.4 | 49 | 6.2 | 9.5 | |||||
Abbreviations: mPFS, median progression free survival; mOS, median overall survival; CCI, Charlson comorbidity index; WHO, World Health Organization; EOR, extent of resection; MGMT, O6-methylguanine-DNA methyltransferase; KPS, Karnofsky Performance Status